Clinical significance of copeptin as an early predictor of renal graft dysfunction in renal transplant recipients

다국어 초록 (Multilingual Abstract)

Background: Copeptin is the carboxyl-terminal part of the vasopressin precursor protein, and its concentration is an independent predictor of the onset of chronic kidney disease and a rapid decline in the glomerular filtration rate. The glomerular filtration rate is regarded as the best indicator of kidney transplant function and is a predictor of graft and patient survival. We investigated the clinical significance of copeptin as an early predictor of renal graft dysfunction in renal transplant recipients.Methods: We measured serum creatinine, cystatin C, and copeptin concentrations in renal transplant recipients on the day of their operation, as well as on postoperative days 3, 7, 30, and 365. Acute rejection was defined as a sudden decrease in renal function accompanied by histological changes.Results: Eight renal transplant recipients were enrolled in the study from July 2018 to December 2019. Four patients experienced histologically confirmed transplant rejection. All four cases involved acute T-cell rejection. No significant correlation was found between the copeptin level and the presence or absence of rejection at any time point. In subgroup analyses, changes in creatinine, the estimated glomerular filtration rate, cystatin, and copeptin did not show statistical significance.Conclusions: We anticipated that copeptin would be useful to identify individuals at high risk of transplant rejection; however, our study failed to show an association. Further research will be needed to overcome the limitations of this study.

참고문헌 (Reference)

• 1 Bardoux P, "Vasopressin increases urinary albumin excretion in rats and humans : involvement of V2 receptors and the renin-angiotensin system" 18 : 497-506, 2003
• 2 Perico N, "V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction" 76 : 960-967, 2009
• 3 Seidah NG, "The complete sequence of a novel human pituitary glycopeptide homologous to pig posterior pituitary glycopeptide" 100 : 901-907, 1981
• 4 Zhu FX, "Serum levels of copeptin are associated with type 2 diabetes and diabetic complications in Chinese population" 30 : 1566-1570, 2016
• 5 Han SS, "Posttransplant hyponatremia predicts graft failure and mortality in kidney transplantation recipients : a multicenter cohort study in Korea" 11 : e0156050-, 2016
• 6 Potier L, "Plasma copeptin and risk of lower-extremity amputation in type 1 and type 2 diabetes" 42 : 2290-2297, 2019
• 7 Mazloum M, "Osmoregulation performance and kidney transplant outcome" 30 : 1282-1293, 2019
• 8 Tasevska I, "Increased levels of copeptin, a surrogate marker of arginine vasopressin, are associated with an increased risk of chronic kidney disease in a general population" 44 : 22-28, 2016
• 9 White C, "Estimating glomerular filtration rate in kidney transplantation : a comparison between serum creatinine and cystatin C-based methods" 16 : 3763-3770, 2005
• 10 Luis-Lima S, "Estimated glomerular filtration rate in renal transplantation : the nephrologist in the mist" 99 : 2625-2633, 2015
• 11 Bouby N, "Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat" 258 (258): F973-F979, 1990
• 12 Mockel M, "Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome(ACS) : a randomized, controlled clinical process study" 36 : 369-376, 2015
• 13 Meijer E, "Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients" 88 : 561-567, 2009
• 14 Villela-Torres ML, "Copeptin plasma levels are associated with decline of renal function in patients with type 2 diabetes mellitus" 49 : 36-43, 2018
• 15 Enhorning S, "Copeptin is an independent predictor of diabetic heart disease and death" 169 : 549-556, 2015
• 16 Malyszko J, "Copeptin in relation to New York Heart Association class in heart transplant recipients and kidney transplant recipients" 42 : 4259-4262, 2010
• 17 Morgenthaler NG, "Copeptin : clinical use of a new biomarker" 19 : 43-49, 2008
• 18 Bouby N, "Contribution of vasopressin to progression of chronic renal failure : study in Brattleboro rats" 65 : 991-1004, 1999
• 19 Morgenthaler NG, "Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin" 52 : 112-119, 2006
• 20 Holwerda DA, "A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization" 28 : 334-339, 1972